Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49


A First-in-Human Clinical Study With TRV734, an Orally Bioavailable G-Protein-Biased Ligand at the μ-Opioid Receptor.

James IE, Skobieranda F, Soergel DG, Ramos KA, Ruff D, Fossler MJ.

Clin Pharmacol Drug Dev. 2020 Feb;9(2):256-266. doi: 10.1002/cpdd.721. Epub 2019 Jul 8.


Understanding the Potential for Patient Engagement in Electronic Consultation and Referral Systems: Lessons From One Safety Net System.

Olayiwola JN, Knox M, Dubé K, Lu EC, Woldeyesus T, James IE, Willard-Grace R, Tuot D.

Health Serv Res. 2018 Aug;53(4):2483-2502. doi: 10.1111/1475-6773.12776. Epub 2017 Sep 20.


Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.

Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR.

Pain. 2014 Sep;155(9):1829-35. doi: 10.1016/j.pain.2014.06.011. Epub 2014 Jun 19.


A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes.

Scully MS, Ort TA, James IE, Bugelski PJ, Makropoulos DA, Deutsch HA, Pieterman EJ, van den Hoek AM, Havekes LM, Dubell WH, Wertheimer JD, Picha KM.

Exp Diabetes Res. 2011;2011:910159. doi: 10.1155/2011/910159. Epub 2011 Jun 30.


Physician communication techniques and weight loss in adults: Project CHAT.

Pollak KI, Alexander SC, Coffman CJ, Tulsky JA, Lyna P, Dolor RJ, James IE, Brouwer RJ, Manusov JR, Østbye T.

Am J Prev Med. 2010 Oct;39(4):321-8. doi: 10.1016/j.amepre.2010.06.005.


Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilage.

Sui Y, Lee JH, DiMicco MA, Vanderploeg EJ, Blake SM, Hung HH, Plaas AH, James IE, Song XY, Lark MW, Grodzinsky AJ.

Arthritis Rheum. 2009 Oct;60(10):2985-96. doi: 10.1002/art.24857.


CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice.

Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka-Doms T, Kwok D, Graden D, Volk A, Nesspor T, James IE, Huang C.

J Biotechnol. 2008 Mar 20;134(1-2):171-80. doi: 10.1016/j.jbiotec.2007.12.005. Epub 2007 Dec 27.


A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

Kumar S, Dare L, Vasko-Moser JA, James IE, Blake SM, Rickard DJ, Hwang SM, Tomaszek T, Yamashita DS, Marquis RW, Oh H, Jeong JU, Veber DF, Gowen M, Lark MW, Stroup G.

Bone. 2007 Jan;40(1):122-31. Epub 2006 Sep 7.


Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

Yamashita DS, Marquis RW, Xie R, Nidamarthy SD, Oh HJ, Jeong JU, Erhard KF, Ward KW, Roethke TJ, Smith BR, Cheng HY, Geng X, Lin F, Offen PH, Wang B, Nevins N, Head MS, Haltiwanger RC, Narducci Sarjeant AA, Liable-Sands LM, Zhao B, Smith WW, Janson CA, Gao E, Tomaszek T, McQueney M, James IE, Gress CJ, Zembryki DL, Lark MW, Veber DF.

J Med Chem. 2006 Mar 9;49(5):1597-612.


Increased osteoblastogenesis and decreased bone resorption protect against ovariectomy-induced bone loss in thrombospondin-2-null mice.

Hankenson KD, James IE, Apone S, Stroup GB, Blake SM, Liang X, Lark MW, Bornstein P.

Matrix Biol. 2005 Aug;24(5):362-70.


An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkey.

Marquis RW, Ward KW, Roethke T, Smith BR, Ru Y, Yamashita DS, Tomaszek TA, Gorycki PD, Cheng HY, James IE, Stroup GB, Lark MW, Gowen M, Veber DF.

Mol Pharm. 2004 Jan 12;1(1):97-100. No abstract available.


Ultrastructural quantification of cell death after injurious compression of bovine calf articular cartilage.

Patwari P, Gaschen V, James IE, Berger E, Blake SM, Lark MW, Grodzinsky AJ, Hunziker EB.

Osteoarthritis Cartilage. 2004 Mar;12(3):245-52.


Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokines.

Patwari P, Cook MN, DiMicco MA, Blake SM, James IE, Kumar S, Cole AA, Lark MW, Grodzinsky AJ.

Arthritis Rheum. 2003 May;48(5):1292-301.


Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.

Miller WH, Manley PJ, Cousins RD, Erhard KF, Heerding DA, Kwon C, Ross ST, Samanen JM, Takata DT, Uzinskas IN, Yuan CC, Haltiwanger RC, Gress CJ, Lark MW, Hwang SM, James IE, Rieman DJ, Willette RN, Yue TL, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1483-6.


Novel bone antiresorptive approaches.

Lark MW, James IE.

Curr Opin Pharmacol. 2002 Jun;2(3):330-7. Review.


A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Lark MW, Stroup GB, James IE, Dodds RA, Hwang SM, Blake SM, Lechowska BA, Hoffman SJ, Smith BR, Kapadia R, Liang X, Erhard K, Ru Y, Dong X, Marquis RW, Veber D, Gowen M.

Bone. 2002 May;30(5):746-53.


Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.

Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW, Ru Y, Vasko-Moser JA, Smith BR, Tomaszek T, Gowen M.

J Bone Miner Res. 2001 Oct;16(10):1739-46.


Azepanone-based inhibitors of human and rat cathepsin K.

Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K, Proksch J, Ward K, Smith B, Levy M, Cummings MD, Haltiwanger RC, Trescher G, Wang B, Hemling ME, Quinn CJ, Cheng HY, Lin F, Smith WW, Janson CA, Zhao B, McQueney MS, D'Alessio K, Lee CP, Marzulli A, Dodds RA, Blake S, Hwang SM, James IE, Gress CJ, Bradley BR, Lark MW, Gowen M, Veber DF.

J Med Chem. 2001 Apr 26;44(9):1380-95.


Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption.

Dodds RA, James IE, Rieman D, Ahern R, Hwang SM, Connor JR, Thompson SD, Veber DF, Drake FH, Holmes S, Lark MW, Gowen M.

J Bone Miner Res. 2001 Mar;16(3):478-86.


Biosynthesis and processing of cathepsin K in cultured human osteoclasts.

Rieman DJ, McClung HA, Dodds RA, Hwang SM, Holmes MW, James IE, Drake FH, Gowen M.

Bone. 2001 Mar;28(3):282-9.


Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat.

Lark MW, Stroup GB, Dodds RA, Kapadia R, Hoffman SJ, Hwang SM, James IE, Lechowska B, Liang X, Rieman DJ, Salyers KL, Ward K, Smith BR, Miller WH, Huffman WF, Gowen M.

J Bone Miner Res. 2001 Feb;16(2):319-27.


Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.

James IE, Marquis RW, Blake SM, Hwang SM, Gress CJ, Ru Y, Zembryki D, Yamashita DS, McQueney MS, Tomaszek TA, Oh HJ, Gowen M, Veber DF, Lark MW.

J Biol Chem. 2001 Apr 13;276(15):11507-11. Epub 2001 Jan 8. Erratum in: J Biol Chem. 2003 Aug 22;278(34):32484.


FrzB-2: a human secreted frizzled-related protein with a potential role in chondrocyte apoptosis.

James IE, Kumar S, Barnes MR, Gress CJ, Hand AT, Dodds RA, Connor JR, Bradley BR, Campbell DA, Grabill SE, Williams K, Blake SM, Gowen M, Lark MW.

Osteoarthritis Cartilage. 2000 Nov;8(6):452-63.


Injurious mechanical compression of bovine articular cartilage induces chondrocyte apoptosis.

Loening AM, James IE, Levenston ME, Badger AM, Frank EH, Kurz B, Nuttall ME, Hung HH, Blake SM, Grodzinsky AJ, Lark MW.

Arch Biochem Biophys. 2000 Sep 15;381(2):205-12.


Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats.

Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J.

J Clin Invest. 2000 Jun;105(11):1595-604.


Differential expression of egr-1 in osteoarthritic compared to normal adult human articular cartilage.

Wang FL, Connor JR, Dodds RA, James IE, Kumar S, Zou C, Lark MW, Gowen M, Nuttall ME.

Osteoarthritis Cartilage. 2000 May;8(3):161-9.


CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues.

Votta BJ, White JR, Dodds RA, James IE, Connor JR, Lee-Rykaczewski E, Eichman CF, Kumar S, Lark MW, Gowen M.

J Cell Physiol. 2000 May;183(2):196-207.


Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.

Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, Newlander KA, Ross ST, Samanen JM, Uzinskas IN, Venslavsky JW, Yuan CC, Haltiwanger RC, Gowen M, Hwang SM, James IE, Lark MW, Rieman DJ, Stroup GB, Azzarano LM, Salyers KL, Smith BR, Ward KW, Johanson KO, Huffman WF.

J Med Chem. 2000 Jan 13;43(1):22-6. No abstract available.


Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis.

Lark MW, Stroup GB, Hwang SM, James IE, Rieman DJ, Drake FH, Bradbeer JN, Mathur A, Erhard KF, Newlander KA, Ross ST, Salyers KL, Smith BR, Miller WH, Huffman WF, Gowen M.

J Pharmacol Exp Ther. 1999 Nov;291(2):612-7.


Development and characterization of a human in vitro resorption assay: demonstration of utility using novel antiresorptive agents.

James IE, Lark MW, Zembryki D, Lee-Rykaczewski EV, Hwang SM, Tomaszek TA, Belfiore P, Gowen M.

J Bone Miner Res. 1999 Sep;14(9):1562-9.


Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Miller WH, Bondinell WE, Cousins RD, Erhard KF, Jakas DR, Keenan RM, Ku TW, Newlander KA, Ross ST, Haltiwanger RC, Bradbeer J, Drake FH, Gowen M, Hoffman SJ, Hwang SM, James IE, Lark MW, Lechowska B, Rieman DJ, Stroup GB, Vasko-Moser JA, Zembryki DL, Azzarano LM, Adams PC, Huffman WF, et al.

Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.


Identification and cloning of a connective tissue growth factor-like cDNA from human osteoblasts encoding a novel regulator of osteoblast functions.

Kumar S, Hand AT, Connor JR, Dodds RA, Ryan PJ, Trill JJ, Fisher SM, Nuttall ME, Lipshutz DB, Zou C, Hwang SM, Votta BJ, James IE, Rieman DJ, Gowen M, Lee JC.

J Biol Chem. 1999 Jun 11;274(24):17123-31.


A novel human bone marrow stroma-derived cell line TF274 is highly osteogenic in vitro and in vivo.

Prabhakar U, James IE, Dodds RA, Lee-Rykaczewski E, Rieman DJ, Lipshutz D, Trulli S, Jonak Z, Tan KB, Drake FH, Gowen M.

Calcif Tissue Int. 1998 Sep;63(3):214-20.


Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR.

J Biol Chem. 1998 Jun 5;273(23):14363-7.


Design of potent and selective human cathepsin K inhibitors that span the active site.

Thompson SK, Halbert SM, Bossard MJ, Tomaszek TA, Levy MA, Zhao B, Smith WW, Abdel-Meguid SS, Janson CA, D'Alessio KJ, McQueney MS, Amegadzie BY, Hanning CR, DesJarlais RL, Briand J, Sarkar SK, Huddleston MJ, Ijames CF, Carr SA, Garnes KT, Shu A, Heys JR, Bradbeer J, Zembryki D, Lee-Rykaczewski L, James IE, Lark MW, Drake FH, Gowen M, Gleason JG, Veber DF.

Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14249-54.


Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.

Votta BJ, Levy MA, Badger A, Bradbeer J, Dodds RA, James IE, Thompson S, Bossard MJ, Carr T, Connor JR, Tomaszek TA, Szewczuk L, Drake FH, Veber DF, Gowen M.

J Bone Miner Res. 1997 Sep;12(9):1396-406.


Cloning and characterization of a novel integrin beta3 subunit.

Kumar CS, James IE, Wong A, Mwangi V, Feild JA, Nuthulaganti P, Connor JR, Eichman C, Ali F, Hwang SM, Rieman DJ, Drake FH, Gowen M.

J Biol Chem. 1997 Jun 27;272(26):16390-7.


Purification and characterization of fully functional human osteoclast precursors.

James IE, Dodds RA, Lee-Rykaczewski E, Eichman CF, Connor JR, Hart TK, Maleeff BE, Lackman RD, Gowen M.

J Bone Miner Res. 1996 Nov;11(11):1608-18.


Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo.

James IE, Dodds RA, Olivera DL, Nuttall ME, Gowen M.

J Bone Miner Res. 1996 Oct;11(10):1453-60.


Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.

Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M.

J Biol Chem. 1996 May 24;271(21):12511-6.


Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone.

Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E, Gowen M.

J Bone Miner Res. 1995 Nov;10(11):1666-80.


Monoclonal antibodies with selective reactivity against osteoblasts and osteocytes in human bone.

Walsh S, Dodds RA, James IE, Bradbeer JN, Gowen M.

J Bone Miner Res. 1994 Nov;9(11):1687-96.


Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

McHugh NJ, Moye DA, James IE, Sampson M, Maddison PJ.

Ann Rheum Dis. 1991 Aug;50(8):548-52.


Autoantibodies to mitochondrial and centromere antigens in primary biliary cirrhosis and systemic sclerosis.

McHugh NJ, James IE, Fairburn K, Maddison PJ.

Clin Exp Immunol. 1990 Aug;81(2):244-9.


Anticardiolipin and antineutrophil antibodies in giant cell arteritis.

McHugh NJ, James IE, Plant GT.

J Rheumatol. 1990 Jul;17(7):916-22.


Papular lesions and cutaneous lupus erythematosus: a comparative clinical and histological study using monoclonal antibodies.

McHugh NJ, Maddison PJ, MacCleod TI, Dean SG, James IE, Goulding NJ, Tan RS.

J Rheumatol. 1988 Jul;15(7):1097-103.


Supplemental Content

Loading ...
Support Center